Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2006

View Archived Issues

BG-00012 safe and reduces brain lesions in relapsing-remitting multiple sclerosis

Gallium maltolate demonstrates effective and safe antibacterial activity in UTI

Lexicon Genetics and BMS extend neuroscience alliance by two years

Neuroprotective effects of NNZ-2556 target delayed cell death

VAS-203 reduces ICP posttraumatic brain injury and improves neurological function

Dosing completed in phase Ib study of AL-208 for neurodegenerative diseases

ICES and MerLion enter antitumor research collaboration

Picoplatin begins phase I/II study in hormone-refractory metastatic prostate cancer

Vion updates pipeline progress

Inspire to file for phase II testing of epinastine for seasonal allergic rhinitis

CytImmune to begin phase I study of CYT-6091 in advanced cancer

Plans for Yondelis filings

Stressgen Biotechnologies changes name to Nventa Biopharmaceuticals

Large outcomes trial planned for Natrecor

Phase III study of glufosfamide recommended to continue to completion

Delay to initiation of phase IIa study of MEM-3454 in Alzheimer's disease

Target enrollment completed in phase IIa study of E1-I.N.T. in type 1 diabetes

Life Science Pharmaceuticals acquires three monoclonal antibody programs

Thelin recommended for approval in Europe

New therapeutic agents for ocular disorders disclosed

Novel treatments for inflammatory disorders reported in recent patents

Patents claim novel therapeutic agents for respiratory disorders

Preliminary phase I/II results suggest MB-07133 warrants further evaluation in HCC

Different administration schedules tested for ZK-304709, an oral multitarget tumor growth inhibitor

Favorable safety, pharmacokinetic and efficacy findings reported for Coramsine

Safety and maximum tolerated dose of imidacrine defined in phase I trials

Phase I/II study reveals good efficacy and safety for TG-1042 in CTCL and CBCL

Intravesical fusion protein associated with excellent tolerability and activity in bladder cancer

New compounds for the treatment of psychiatric disorders reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...